Dogwood Therapeutics (DWTX) Share-based Compensation (2020 - 2026)

Dogwood Therapeutics has reported Share-based Compensation for 7 years, with the latest figure at $5.3 million in Q2 2026.

• On a quarterly basis, Share-based Compensation rose 2685.39% year-over-year to $5.3 million in Q2 2026; TTM through Jun 2026 was $5.3 million, a 2685.39% increase from a year earlier, with the FY2025 full-year figure at $4.7 million, up 891.52% from the prior year.
• Share-based Compensation was $5.3 million for Q2 2026 at Dogwood Therapeutics, up from $1.8 million in the prior quarter.
• The five-year high for Share-based Compensation was $5.3 million in Q2 2026, with the low at $84474.0 in Q1 2025.
• Average Share-based Compensation over 5 years is $1.0 million, with a median of $539615.0 recorded in 2022.
• The sharpest annual moves came in 2024 and 2026: Share-based Compensation sank 94.29% in 2024, then jumped 2685.39% in 2026.
• Over 5 years, Share-based Compensation stood at $149530.0 in 2022, then slipped by 0.82% to $148306.0 in 2023, then slumped by 36.75% to $93802.0 in 2024, then soared by 68.29% to $157860.0 in 2025, then surged by 3268.9% to $5.3 million in 2026.
• The last three Share-based Compensation figures came in at $5.3 million (Q2 2026), $1.8 million (Q1 2026), and $157860.0 (Q4 2025), per Business Quant data.